BioVectra

BioVectra is a leading North American CDMO specializing in the development and GMP manufacturing of biologics, small molecules—including highly potent APIs—and nucleic acid-based therapeutics such as mRNA and pDNA. The company operates state-of-the-art facilities in Atlantic Canada with expertise spanning microbial fermentation, synthetic organic chemistry, downstream processing, formulation development, MPEG production/conjugation chemistry. It serves many of the world’s top pharmaceutical companies with full-service outsourcing solutions from early-stage clinical to large-scale commercial manufacturing. In July 2024 it was acquired by Agilent Technologies Inc.